ANIP vs MNKD: fair value comparison
ANI Pharmaceuticals, Inc. and MannKind Corporation · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ANIP currently sits closer to the top of our discount ranking. MNKD carries the stronger quality grade.
| ANIP | MNKD | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $80.06 | $3.80 |
| 12-month range | $75.22–$94.06 | $2.54–$6.01 |
| Sector rank | #12 of 113 Healthcare | #17 of 113 Healthcare |
| Quality grade | C- | A |
| Leverage | Moderate | Low |
| Margin trend | — | Expanding |
| Revenue growth | — | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | — | Overvalued |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: ANIP fair value analysis · MNKD fair value analysis